EC approves Jazz Pharmaceutical’s narcolepsy and sleep apnoea treatment

Jazz Pharmaceuticals has received a European Marketing Authorisation for solriamfetoli as a treatment for excessive daytime sleepiness in adults with narcolepsy and obstructive sleep apnoea. The company announced that The European Commission (EC) has accepted the drug to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy as well as obstructive sleep apnoea (OSA),

Continue Reading

Minds are like parachutes; they work best when open – Read our latest Regulatory Affairs Report

The latest CPIA report features analysis and data from the Regulatory Affairs sector within the pharmaceutical industry for UK, Ireland, Germany, Switzerland, Belgium, Netherlands, and Luxembourg. Clinical Professionals Group CEO, Yvette Cleland comments: To view the full report and previous editions, please visit the CPIA report on the Clinical Professionals website here.  If you would

Continue Reading

FDA approves SK Biopharma’s seizure drug

FDA has given Arvelle Therapeutics’ Xcopri the go-ahead for partial-onset seizures in adults. The emerging company, which is part of a subsidiary of SK Biopharmaceuticals, announced that it has also licensed exclusive rights to develop and commercialise the drug in Europe, with intent to file a Marketing Authorisation Application (MAA) in the first half of

Continue Reading

Regulatory Professionals attends TOPRA 2019 Symposium

Regulatory Professionals were delighted to exhibit again at the TOPRA symposium, the biggest event in the organisation’s history for a few years, drawing over 650 delegates and exhibitors.  With representation across industry from pharmaceutical, veterinary medicines and medical device sectors, plus patient groups, charities, healthcare professions, and more.  The presentations and sessions were hugely insightful

Continue Reading